Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

High-Dose Convalescent Plasma for Treatment of Severe COVID-19

2022; Centers for Disease Control and Prevention; Volume: 28; Issue: 3 Linguagem: Inglês

10.3201/eid2803.212299

1080-6059

Gil Cunha De Santis, Luciana Correa Oliveira de Oliveira, Pedro Manuel Marques Garibaldi, Carlos Eduardo L. Almado, Júlio Croda, Ghislaine G.A. Arcanjo, Erika Abdon Oliveira, Adriana Coracini Tonácio, Dante Mário Langhi, José Orlando Bordin, Renato N. Gilio, Leonardo Carvalho Palma, Elaine Vieira Santos, Simone Kashima, Benedito Pina Almeida Prado, Marjorie Cornejo Pontelli, Rogério Gomes, Carlos Henrique Miranda, Maria Auxiliadora Parreiras Martins, Dimas Tadeu Covas, Eurico Arruda, Benedito A. Lopes da Fonseca, Rodrigo T. Calado,

COVID-19 and Mental Health

To assess whether high-dose coronavirus disease (COVID-19) convalescent plasma (CCP) transfusion may benefit patients with severe COVID-19, we conducted a multicenter randomized trial in Brazil. Patients with severe COVID-19 who were within 10 days of initial symptom onset were eligible. Patients in the CCP group received 3 daily doses of CCP (600 mL/d) in addition to standard treatment; control patients received standard treatment only. Primary outcomes were death rates at days 30 and 60 of study randomization. Secondary outcomes were ventilator-free days and hospital-free days. We enrolled 107 patients: 36 CCP and 71 control. At day 30, death rates were 22% for CCP and 25% for the control group; at day 60, rates were 31% for CCP and 35% for control. Needs for invasive mechanical ventilation and durations of hospital stay were similar between groups. We conclude that high-dose CCP transfused within 10 days of symptom onset provided no benefit for patients with severe COVID-19.